• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

byThomas SuandDeepti Shroff Karhade
September 1, 2020
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients who received low-dose colchicine daily had a ~30% lower risk of cardiovascular events compared to those who received placebo.

2. Although the incidence of cardiovascular death was similar between groups, the colchicine group had a numerically greater number of non-cardiovascular deaths as well as all-cause deaths compared to the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Colchicine is an anti-inflammatory drug that exerts its effects through inhibition of microtubule assembly, thereby reducing inflammasome activation and modulating leukocyte responsiveness. The Colchicine Cardiovascular Outcomes Trial (COLCOT) found that daily use of colchicine soon after myocardial infarction reduced the risk of further ischemic cardiovascular events and the previous Low-Dose Colchicine (LoDoCo) pilot trial found that patients with stable coronary disease who received colchicine were significantly less likely to experience acute cardiovascular events compared to those who did not. This randomized, placebo-controlled trial, termed LoDoCo2, confirmed the association between colchicine use and decreased risk of cardiovascular events using a patient population that was roughly 10 times larger than the first. This benefit became detectable early in the study and persisted with no attenuation over 5 years of treatment. Adverse events such as cancer, infection, pneumonia, and gastrointestinal upset occurred at similar rates between groups. While not quite statistically significant, the incidence rate of non-cardiovascular death was higher in the colchicine group compared to placebo. This study circumvented many weaknesses of the original LoDoCo trial, including a small sample size and the lack of placebo control, but some limitations still remained, such as the lack of data on blood pressure, lipid levels, and biomarkers of inflammation. Overall, the results of the LoDoCo2 trial lend further support to the effectiveness of colchicine in reducing the occurrence of cardiovascular events in patients with chronic coronary disease.

Click here to read the study, published today in NEJM

Relevant Reading: Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

RELATED REPORTS

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin

In-Depth [randomized controlled trial]: In this multicenter study beginning in August 2014, 5222 patients between 35 and 82 years of age with evidence of coronary disease entered a 1-month open-label run-in phase before being randomly assigned in a 1:1 ratio to either continue receiving 0.5 mg colchicine daily or begin receiving placebo. Patients with moderate-to-severe renal impairment, severe heart failure, or severe valvular heart disease were excluded. The primary endpoint, a composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, and ischemia-driven coronary revascularization, occurred in 187 patients (6.8%) in the colchicine group and 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events, respectively, per 100 person-years; hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). This effect was consistent across subgroups defined according to age, sex, smoking status, diabetes, renal function, hypertension, and statin dose. Between-group differences were also detected in the first five pre-ranked secondary endpoints, all of which were different combinations of the individual components noted above (P<0.01 for all). However, both groups had similar cardiovascular mortality (20 vs. 25 fatalities; HR, 0.80; 95% CI, 0.44 to 1.44), non-cardiovascular mortality (53 vs. 35 fatalities; HR, 1.51; 95% CI, 0.99 to 2.31), and all-cause mortality (incidence, 0.9 vs. 0.8 events, respectively, per 100 person-years; HR, 1.21; 95% CI, 0.86 to 1.71).

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colchicinecoronary revascularizationischemic heart diseasestatin
Previous Post

#VisualAbstract: Targeted intraoperative radiotherapy associated with similar outcomes as whole breast post-operative radiotherapy for breast cancer

Next Post

Chest radiograph neural network predicts lung cancer in smokers

RelatedReports

Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

June 10, 2025
PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events

March 3, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin

October 30, 2024
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Cardiology

Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy 

October 15, 2024
Next Post
Severity of emphysema on pulmonary CT may predict lung cancer location

Chest radiograph neural network predicts lung cancer in smokers

#VisualAbstract: Better glucose control with closed-loop system in children with type 1 diabetes

#VisualAbstract: For-profit long term care homes associated with increased extent of COVID-19 outbreaks and related mortality

Prescription of antibiotics for acute respiratory infections increasing

Proadrenomedullin predicts severe community-acquired pneumonia among children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.